Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

NCT05305859 PHASE2 RECRUITING

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML

Details

Lead sponsor	The First Affiliated Hospital of Xiamen University
Phase	PHASE2
Status	RECRUITING
Enrolment	30
Start date	Wed Jan 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Leukemia, Myeloid, Acute
• Relapsed Adult AML
• Refractory Leukemia

Interventions

• venetoclax combining chidamide and azacitidine (VCA)

Countries

China